Tumor-associated antigens (presented by dendritic cell-tumor fusion hybrids) (TAA (DC-tumor fusion))

Tumor-associated antigens (TAAs) presented by dendritic cell (DC)-tumor fusion hybrids represent a sophisticated approach to cancer immunotherapy that leverages the full antigenic spectrum of a patient's malignancy [1]. By fusing autologous dendritic cells with whole tumor cells, the resulting hybrid cells (fusion cells) combine the potent costimulatory and antigen-processing machinery of DCs with the diverse repertoire of known and unidentified antigens from the tumor [2]. This platform facilitates the presentation of TAAs through both MHC class I and class II pathways, enabling the simultaneous activation of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells [3]. Unlike single-antigen vaccines, this strategy targets multiple epitopes, which helps prevent tumor escape through antigen loss or mutation [4]. Clinically, these fusion hybrids have been evaluated as autologous vaccines in various cancers, showing the ability to induce durable immune responses and, in some cases, clinical remissions in patients with hematological and solid tumors [5]. The primary therapeutic challenge remains the labor-intensive nature of producing personalized vaccines and the potential for inducing autoimmunity if the targeted antigens are also expressed on healthy tissues [6]. Sources: [1] Koido S, et al. (2013). Int J Mol Sci. [2] Avigan D, et al. (2004). Clin Cancer Res. [3] Rosenblatt J, et al. (2011). Blood. [4] Gong J, et al. (2000). J Immunol. [5] Avigan D, et al. (2016). Nature Reviews Clinical Oncology. [6] Trefzer U, et al. (2004). Gene Therapy.

Other names

DC-tumor fusion antigensDendritic cell-tumor cell hybridsFusion cell vaccinesFC vaccinesDC-tumor fusions

The mechanism involves the fusion of patient-derived dendritic cells with autologous tumor cells, creating a hybrid cell that expresses the full array of tumor-associated antigens (TAAs) alongside DC-derived costimulatory molecules (CD80, CD86) and MHC molecules [1, 2]. These hybrids process TAAs through both endogenous and exogenous pathways, leading to the presentation of peptides on MHC class I and II molecules, which subsequently activates a broad, polyclonal population of CD8+ cytotoxic T lymphocytes and CD4+ helper T cells [3].